Post-Transplantation Cyclophosphamide and Tacrolimus for Graft-versus-Host Disease Prevention after Allogeneic Hematopoietic Cell Transplantation from HLA-Matched Donors Has More Advantages Than Limitations

Salas, María Queralt; Pedraza, Alexandra; Charry, Paola; Suárez-Lledó, María; Rodríguez-Lobato, Luis Gerardo; Brusosa, Marc; Solano, María Teresa; Serrahima, Anna; Nomdedeu, Meritxell; Cid, Joan; Lozano, Miquel; Arcarons, Jordi; de Llobet, Noemi; Rosiñol, Laura; Esteve, Jordi; Urbano-Ispizua, Álvaro; Carreras, Enric; Fernández-Avilés, Francesc; Rovira, Montserrat; Martinez, Carmen

doi:10.1016/j.jtct.2023.11.020

Cited by 5 publications

(1 citation statement)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the subsequent years, its use was progressively extended to allo-HCT performed from all donor types, becoming our institutional GVHD prophylaxis for all allo-HCT in 2019. 15 Peripheral blood was the most prevalent stem cell source. However, bone marrow stem cell grafts were accepted as per donor preference or occasionally in the haploidentical-HCT setting.…”

Section: Allo-hct Information and Main Outcome Definitionsmentioning

confidence: 99%

Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group

Jiménez‐Vicente,

Charry,

Castaño‐Diez

et al. 2024

Br J Haematol

Self Cite

View full text Add to dashboard Cite

SummaryEuropean LeukemiaNet refined their risk classification of acute myeloid leukaemia (AML) in 2022 (ELN 2022) according to the two new myeloid classifications published the same year. We have retrospectively assessed the prognostic value of the ELN 2022 in 120 AML patients undergoing allogeneic haematopoietic cell transplantation (allo‐HCT), including 99 in first complete response (CR1) from 2011 to 2021 in our centre. Adverse risk patients (Adv) presented inferior outcome in terms of overall survival (OS) and leukaemia‐free survival (LFS) (OS [p = 0.003], LFS [p = 0.02]), confirmed in multivariate analysis (hazard ratio [HR] for OS = 2.00, p = 0.037). These results were also seen in patients allografted in CR1. Further analysis identified a subgroup named adverse‐plus (AdvP), including complex karyotype, MECOM(EVI1) rearrangements and TP53 mutations, with worse outcomes than the rest of groups of patients, including the Adv (HR for OS: 3.14, p < 0.001, HR for LFS: 3.36, p < 0.001), with higher 2‐year cumulative incidence of relapse (p < 0.001). Notably, within this analysis, the outcome of Adv and intermediate patients were similar. These findings highlight the prognostic value of ELN 2022 in patients undergoing allo‐HCT, which can be improved by the recognition of a poor genetic subset (AdvP) within the Adv risk group.

show abstract

Section: Allo-hct Information and Main Outcome Definitionsmentioning

confidence: 99%